Search the Newsreel

NeuroOne Medical Technologies Corp (NMTC) (Q3 2026) Earnings Call Highlights: Revenue Grows 16% But Supply Chain Constraints Force Guidance Cut

NeuroOne Medical Technologies Corp (NMTC) reported a 16% increase in Q3 fiscal 2026 product revenue and strong order growth, with significant gross margin expansion. Despite positive developments like ISO 13485 certification and progress in drug delivery platforms, the company faced significant manufacturing and supply …

Why Medipharm Labs Corp stock is skyrocketing today

NMTC Q2 2026 Earnings: EPS Miss Widens Net Loss to -$0.28 Despite 1.86% Share Gain - Cost Structure Review

Here is Why Growth Investors Should Buy Globus Medical (GMED) Now

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. By their very …

Is Outfront Media (OUT) a Solid Growth Stock? 3 Reasons to Think "Yes"

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. That's because, these …

Revolution Medicines stock hits all-time high at 208.77 USD

Revolution Medicines Inc. (RVMD) stock reached an all-time high of $208.77, currently trading at $208.48, reflecting a remarkable 468.97% increase over the past year. Despite being considered overvalued by InvestingPro analysis, the company closed Q2 with $3.9 billion in cash and investments and is …

Baosheng Media to acquire 40% stake in Blue Intelligence Cloud Innovation Technology

Baosheng Media has entered into a non-binding memorandum to acquire a 40% equity interest in Blue Intelligence Cloud Innovation Technology. The acquisition aims to expand Baosheng's reach into AI marketing, including AI-driven traffic acquisition, user analytics, content generation, and marketing conversion. Blue Intelligence Cloud …

Core Thesis on Lifecore Biomedical (LFCR): Monetizing Excess Production

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the …

Praxis Precision Medicines stock hits 52-week high at 388.27 USD

Praxis Precision Medicines (PRAX) stock has reached a new 52-week high of $388.27, marking a 721.64% increase over the past year with a market capitalization of $10.77 billion. Despite being unprofitable, this surge reflects investor confidence and recent positive developments, including a narrower-than-expected Q2 …

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …

Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22

Morgan Stanley has reiterated its "Buy" rating on Generate Biomedicines (GENB.US), maintaining its target price at $22. This suggests a continued positive outlook on the company's stock performance from the financial institution.

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

Kahn Swick & Foti, LLC (KSF) has initiated an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) regarding potential breaches of fiduciary duties by its officers and directors. This follows a report by Scorpion Capital alleging fraudulent billing, coercive business practices, and unsafe organ transplantation, …

ICU Medical (ICUI): Buy, Sell, or Hold Post Q2 Earnings?

CorMedix (NASDAQ:CRMD) Shares Up 7.3% on Analyst Upgrade

CorMedix (NASDAQ:CRMD) shares increased by 7.3% following Royal Bank of Canada's upgrade of its price target from $13 to $14, maintaining an "outperform" rating. The company also surpassed its Q2 earnings and revenue estimates, reporting $0.29 EPS against a $0.24 estimate and $101.93 million …

Baosheng Media signs MoU to acquire 40% stake in AI firm

Baosheng Media Group Holdings Limited has signed a non-binding memorandum of understanding to acquire a 40% equity interest in Blue Intelligence Cloud Innovation Technology (Beijing) Co., Ltd. This strategic move aims to integrate AI-powered capabilities like intelligent marketing and data analytics into Baosheng's services, …

Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year High - What's Next?

China Medical System lifts H1 earnings as innovative drugs drive growth

China Medical System Declares Interim Dividend for First Half of 2026

China Medical System: Innovative products fueled double-digit growth, with strong R&D and global expansion momentum

Singapore Shares Stay in Green as Trade Surplus Shrinks; Medi Lifestyle Soars 44%

Why Medicenna Therapeutics Corp stock surged yesterday

Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)?

Globus Medical (GMED) reported second-quarter 2026 results with increased sales but a decline in net income and EPS, reaffirming its full-year revenue outlook. The company's investment case hinges on translating revenue growth into durable profits amidst integration and cost control challenges from acquisitions. While …

Resilient Fresenius Medical Care stock holds its ground as dividend and consensus support valuation

Fresenius Medical Care (FMS) stock closed at $23.75 on August 14, 2026, near the analyst consensus price target of $23.57, suggesting a fair valuation. The company offers an annual dividend of $0.61 per share, translating to a 2.57% yield with a payout ratio of …

Medical Properties Trust, Inc. Stock 12‑Month Price Target Cut to $5.11, Implies 22% Upside

Medical Properties Trust, Inc. (MPT) has seen its average 12-month price target reduced from $5.21 to $5.11 by analysts, with a range of $4.25 to $7 per share. This new target suggests a potential 22% upside from its August 14th closing price. The consensus …

Gaush Meditech Grants Heidelberg Exclusive Global Rights to T3 Corneal Imaging System

IceCure Medical (NASDAQ: ICCM) director lists no shares

IceCure Medical Ltd. director David Salton filed an initial Form 3, reporting his status as a director of the company. This filing indicates no specific equity holdings, derivative positions, or transactions at this time, meaning David Salton does not currently report any direct or …

IceCure Medical : Initial Statement of Beneficial Ownership (Form 3)

This article reports that IceCure Medical (ICCM) director, David Salton, filed an Initial Statement of Beneficial Ownership of Securities (Form 3) with the SEC on August 17, 2026. This form indicates that Salton became a reporting person on August 12, 2026, due to his …

IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake

IceCure Medical Ltd. (NASDAQ: ICCM) has granted 73,890 restricted share units (RSUs) to its VP Human Resources, Dotan Merav Nir, as a compensation-related equity award on August 14, 2026. This grant increases his total holdings to 76,168 ordinary shares and RSUs. The new RSUs …

IceCure Medical (ICCM) director Chan Vincent leaves board

IceCure Medical Ltd. (ICCM) director Chan Vincent Chun Hung has ceased serving on the board as of August 12, 2026. This departure means he is no longer subject to Section 16 reporting obligations, and no insider transactions were reported in connection with his exit. …

IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0

IceCure Medical Ltd.'s CFO, Meir Peleg, was granted 181,483 restricted share units (RSUs) on August 14, 2026, at a price of $0.00 per share-equivalent. These RSUs have a vesting schedule where 25% vest on August 11, 2027, and the remaining 75% vest in twelve …

APYX Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprise Reaches 16.27% - Earnings Call Highlights

Profound Medical (NASDAQ: PROF) targets higher TULSA throughput

Profound Medical Corp. (NASDAQ: PROF) has introduced new real-time interventional MRI Treatment Delivery Consol (TDC) software for its TULSA-PRO® prostate ablation platform. This software aims to enhance procedural efficiency and physician experience, potentially increasing the number of TULSA Procedures™ per system per day from …

Some physicians report four TULSA procedures a day—what changes next?

Profound Medical (NASDAQ: PROF) has introduced new Treatment Delivery Consol (TDC) software for its TULSA-PRO® platform, aiming to increase procedural efficiency and allow surgeons to perform up to six TULSA Procedures™ per day. The upgrade enhances real-time interventional MRI control and physician-requested interface improvements, …

MDIA Q3 2023 Earnings: Net Loss of $0.11 Per Share Highlights Radio Ad Market Challenges - Operating Margin Analysis

TYK Medicines Narrows Interim Loss as Other Income Surges Despite Higher R&D Spend

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital International (MSCI). The change …